In patients with early septic shock, the ANDROMEDA‑SHOCK‑2 randomized clinical trial evaluated a personalized hemodynamic resuscitation protocol targeting normalization of capillary refill time.
Compared with usual care, this strategy was superior for a hierarchical composite outcome of mortality, duration of vital support, and length of hospital stay at 28 days, with the overall benefit primarily attributable to a shorter duration of organ support. 🧵